COVID-19 treatment, Keytruda boost drugmaker Merck in Q1

Apr 27, 2022, 3:38 PM | Updated: Apr 28, 2022, 8:45 am
FILE - This undated photo provided by Merck & Co. shows their new antiviral medication molnupiravir...

FILE - This undated photo provided by Merck & Co. shows their new antiviral medication molnupiravir. COVID-19 patients have two new treatment options that can be taken at home. But that convenience comes with a catch: The pills have to be taken as soon as possible once symptoms appear. U.S. regulators authorized the pills from Pfizer and Merck late 2021. (Merck & Co. via AP, File)

(Merck & Co. via AP, File)

Merck soared past first-quarter expectations, helped by sales of its long-standing blockbuster cancer drug Keytruda and a new COVID-19 treatment that also topped forecasts.

The drugmaker raised its 2022 forecast Thursday after its coronavirus treatment molnupiravir brought in almost $3.2 billion in sales in the quarter.

Analysts were expecting $2.54 billion from the drug, which debuted late last year under the brand name Lagevrio.

Merck has said it expects the capsules to bring in sales of $5 billion or more this year. But analysts are starting to wonder whether all the treatment courses Merck makes will get used.

One analyst said on a Thursday call with company leaders that some data shows the treatment Paxlovid from rival Pfizer is being used much more frequently. The analyst noted that the U.S. has contracted to have 3.1 million courses of Lagevrio delivered and asked if there was a recourse for the government to return unused portions.

Chief Financial Officer Caroline Litchfield said the company expects the roughly 6.4 million treatment courses that it has delivered so far globally to be used over time, and the drugmaker remains “confident in our financials.”

She said data they have access to suggests that 500,000 people have used Lagevrio so far globally, and use has been particularly strong outside the United States.

Governments have been using and stockpiling both Lagevrio, which is also made by Ridgeback Biotherapeutics, and Paxlovid, which was shown to be more effective in clinical research, after the omicron surge of the virus filled hospitals earlier this year.

The treatments have been seen as a breakthrough in the fight to control the ongoing pandemic because they are effective and are easier for patients to use than other drugs that require injections or IV infusions.

The drugs are being used to treat patients most at risk of winding up in a hospital from the virus.

Both Lagevrio and Paxlovid must be used soon after COVID-19 symptoms appear, and U.S. President Joe Biden is pushing to expand their availability.

The treatments are free to patients in the U.S.

Not counting Lagevrio, Merck said its pharmaceutical revenue still grew 18% in the first quarter. Sales of Keytruda climbed 23% to $4.81 billion.

Overall, Merck’s profit climbed 36% to $4.31 billion.

Adjusted earnings, which exclude one-time items, totaled $2.14 per share. Total sales jumped 50% to $15.9 billion.

Analysts expected, on average, earnings of $1.83 per share on about $14.55 billion in revenue in the quarter.

The company also said Thursday it was raising and narrowing its forecast for the year. Merck now expects adjusted earnings to range between $7.24 and $7.36 per share after forecasting $7.12 to $7.27 per share in February.

Analysts expect earnings of $7.28 per share, according to FactSet.

Shares of Merck & Co. Inc., based in Kenilworth, New Jersey, climbed more than 3% to $87.38 late Thursday morning. The Dow Jones Industrial Average, of which Merck is a component, rose slightly.


Follow Tom Murphy on Twitter:

Copyright © The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.


Associated Press

Google’s artificially intelligent ‘Bard’ set for next stage

Google announced Tuesday it's allowing more people to interact with “ Bard,” the artificially intelligent chatbot the company is building to counter Microsoft's early lead in a pivotal battleground of technology.
13 hours ago
Evelyn Knapp, a supporter of former President Donald, waves to passersby outside of Trump's Mar-a-L...
Associated Press

Trump legal woes force another moment of choosing for GOP

From the moment he rode down the Trump Tower escalator to announce his first presidential campaign, a searing question has hung over the Republican Party: Is this the moment to break from Donald Trump?
2 days ago
FILE - The Silicon Valley Bank logo is seen at an open branch in Pasadena, Calif., on March 13, 202...
Associated Press

Army of lobbyists helped water down banking regulations

It seemed like a good idea at the time: Red-state Democrats facing grim reelection prospects would join forces with Republicans to slash bank regulations — demonstrating a willingness to work with President Donald Trump while bucking many in their party.
2 days ago
FILE - This Sept. 2015, photo provided by NOAA Fisheries shows an aerial view of adult female South...
Associated Press

Researchers: Inbreeding a big problem for endangered orcas

People have taken many steps in recent decades to help the Pacific Northwest's endangered killer whales, which have long suffered from starvation, pollution and the legacy of having many of their number captured for display in marine parks.
3 days ago
FILE - Hiring signs are displayed at a grocery store in Arlington Heights, Ill., Jan. 13, 2023. Emp...
Associated Press

Pay transparency is spreading. Here’s what you need to know

U.S. employers are increasingly posting salary ranges for job openings, even in states where it’s not required by law, according to analysts with several major job search websites.
3 days ago
Meadowdale High School 9th grade students Juanangel Avila, right, and Legacy Marshall, left, work t...
David Klepper and Manuel Valdes, Associated Press

Seattle high school teacher advocates for better digital literacy in schools

Shawn Lee, a high school social studies teacher in Seattle, wants to see lessons on internet akin to a kind of 21st century driver's education, an essential for modern life.
3 days ago

Sponsored Articles

SHIBA volunteer...

Volunteer to help people understand their Medicare options!

If you’re retired or getting ready to retire and looking for new ways to stay active, becoming a SHIBA volunteer could be for you!
safety from crime...

As crime increases, our safety measures must too

It's easy to be accused of fearmongering regarding crime, but Seattle residents might have good reason to be concerned for their safety.
Comcast Ready for Business Fund...
Ilona Lohrey | President and CEO, GSBA

GSBA is closing the disparity gap with Ready for Business Fund

GSBA, Comcast, and other partners are working to address disparities in access to financial resources with the Ready for Business fund.

Medicare open enrollment is here and SHIBA can help!

The SHIBA program – part of the Office of the Insurance Commissioner – is ready to help with your Medicare open enrollment decisions.
Lake Washington Windows...

Choosing Best Windows for Your Home

Lake Washington Windows and Doors is a local window dealer offering the exclusive Leak Armor installation.
Anacortes Christmas Tree...

Come one, come all! Food, Drink, and Coastal Christmas – Anacortes has it all!

Come celebrate Anacortes’ 11th annual Bier on the Pier! Bier on the Pier takes place on October 7th and 8th and features local ciders, food trucks and live music - not to mention the beautiful views of the Guemes Channel and backdrop of downtown Anacortes.
COVID-19 treatment, Keytruda boost drugmaker Merck in Q1